New light treatment could replace surgery for cervical precancer
NCT ID NCT07634497
First seen Jun 10, 2026 · Last updated Jun 18, 2026 · Updated 2 times
Summary
This study tests a light-activated drug (HAL-PDT) to treat cervical precancer (CIN2) in 500 women aged 18-50. The treatment is guided by how the cervix responds, with up to 4 sessions. The main goal is to see if the abnormal cells shrink or disappear within 6 months, avoiding the need for surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL INTRAEPITHELIAL NEOPLASIA GRADE 2 (CIN2) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.